Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Catalyst Pharmaceuticals Joins Elite List Of Stocks With 95-Plus Composite Rating

On Monday, Catalyst Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 92 to 96.

The upgrade means the stock is now outperforming 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.

Catalyst Pharmaceuticals is currently forming a consolidation, with a 17.50 entry. Look for the stock to break out in volume at least 40% above average.

Looking For The Best Stocks To Buy And Watch? Start Here

The stock earns an 82 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 82% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

In Q1, the company posted -7% earnings growth. Top line growth fell to 15%, down from 82% in the previous quarter.

Catalyst Pharmaceuticals holds the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly-rated stocks within the group.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.